C2I GENOMICS
C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations. The cancer intelligence company is developing a platform that can perform whole-genome sequencing using only 2 milliliters of blood. Its ultra-sensitive liquid biopsy assay allows physicians to monitor patient treatment response and detect treatment failure or disease recurrence months and potentially years earlier than current monitoring methods. C2i’s cancer diagnostics service uses ... artificial intelligence pattern recognition and the whole-genome analysis to spot trace amounts of cancer much quicker, in about a week, to inform better treatment decisions and ultimately save lives. The company aims to help patients avoid unnecessary overtreatment with toxic chemotherapy or radiation, as well as to prevent them from going without treatment while cancer quietly grows and metastasizes. In 2019, Boris Oklander, Asaf Zviran, and Ezra Sofer established the company in New York, New York.
C2I GENOMICS
Industry:
Genetics Health Care Health Diagnostics Therapeutics
Founded:
2019-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.c2i-genomics.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
112 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Denali Therapeutics
Denali Therapeutics is dedicated to defeating neurodegenerative diseases to deliver safe and effective medicines to patients and families.
Human Longevity
Human Longevity is a genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived.
METiS Therapeutics
METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Current Advisors List
Current Employees Featured
Founder
Investors List
iGlobe Partners
iGlobe Partners investment in Series B - C2i Genomics
Duquesne Family Office
Duquesne Family Office investment in Series B - C2i Genomics
Alexandria Real Estate Equities
Alexandria Real Estate Equities investment in Series B - C2i Genomics
LionBird
LionBird investment in Series B - C2i Genomics
Section 32
Section 32 investment in Series B - C2i Genomics
Driehaus Capital Management
Driehaus Capital Management investment in Series B - C2i Genomics
Casdin Capital
Casdin Capital investment in Series B - C2i Genomics
NFX
NFX investment in Series B - C2i Genomics
The Mark Foundation for Cancer Research
The Mark Foundation for Cancer Research investment in Series B - C2i Genomics
Silver Lake
Silver Lake investment in Series B - C2i Genomics
Official Site Inspections
http://www.c2i-genomics.com Semrush global rank: 3.75 M Semrush visits lastest month: 3.6 K
- Host name: server-3-167-112-82.iad55.r.cloudfront.net
- IP address: 3.167.112.82
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "C2i Genomics"
Cancer care startup C2i Genomics acquired by Veracyte …
Jan 8, 2024 Israeli startup C2i Genomics is being acquired by cancer diagnostics company Veracyte for up to $95 million. Under the terms of the agreement, Veracyte will pay $70 million in Veracyte shares at closing, and up …See details»
C2i Genomics - Funding, Financials, Valuation & Investors
C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations. Search Crunchbase. Start Free Trial . Chrome Extension. ... How much funding …See details»
Veracyte acquires C2i Genomics - 2024-01-08 - Crunchbase
Jan 8, 2024 Veracyte acquires C2i Genomics on 2024-01-08 for $70000000. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. ... C2i …See details»
JPM24: Veracyte inks $95M deal to buy fellow cancer …
Jan 9, 2024 With an eye toward expanding the reach of its cancer diagnostics portfolio, Veracyte has made moves to pick up C2i Genomics, maker of tests to detect the minimal residual disease, or MRD, left ...See details»
Veracyte Announces Preliminary Full-Year 2023 Results ... - Nasdaq
Dec 31, 2023 C2i Genomics’ whole-genome, artificial intelligence-powered approach generates broad signatures from blood more quickly and efficiently than bespoke panels. The company’s …See details»
ASCO: Inside C2i Genomics’ precision oncology ‘one …
Jun 3, 2023 Boris Oklander, Ph.D., another C2i co-founder and its chief technology officer, described that future offering as a “one-stop shop for precision oncology” in Friday’s interview.See details»
Why C2i is the World's First Platform for Cancer …
NFX was an early stage investor in C2i due to their long-term vision and world-changing technology. Listen to NFX Partner Omri Amirav-Drory talk with Asaf Zviran, Co-founder & CEO of C2i Genomics, about the future of their …See details»
C2i Genomics Raises $12 Million in Series A Funding
Jun 9, 2020 C2i Genomics’ innovative solution is based on research performed at the New York Genome Center (NYGC) and Weill Cornell Medicine (WCM) by Dr. Zviran, along with Dr. Dan Landau, core faculty ...See details»
C2i Genomics lands $100M to scale up software that detects tiny …
Apr 16, 2021 At barely two years old, C2i Genomics is already going through a major growth spurt. The company, which is developing a blood test to detect residual cancer cells after …See details»
C2i, a genomics SaaS product to detect traces of …
Apr 15, 2021 C2i Genomics has developed software that’s 100x more sensitive in detecting residual disease, and investors are pouncing on the potential. Today, C2i announced a $100 million Series B led by ...See details»
C2i Genomics - Contacts, Employees, Board Members
Organization. C2i Genomics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 5. Number of …See details»
Veracyte Adds AI-Driven MRD Testing Capabilities with C2i …
Jan 10, 2024 Veracyte announced it has reached a definitive agreement to acquire C2i Genomics, expanding its diagnostics platform to include whole-genome minimal residual …See details»
C2i Genomics Expands AI-Powered Cancer Detection and
Oct 13, 2021 Founded in 2019, C2i Genomics has created the world’s leading cancer treatment intelligence platform that uses low-input blood (only 2mL blood) whole-genome sequencing to …See details»
C2i Genomics Partners with Twist Bioscience to Launch Reference ...
Feb 8, 2022 About C2i Genomics. Founded in 2019, C2i Genomics has created the world’s leading cancer treatment intelligence platform that uses low-input blood (only 2mL blood) …See details»
A sensitive strategy for tumour surveillance - Nature
Jun 24, 2021 C2i Genomics is a spin-off from the New York Genome Center, New York City, and one of the final eight for The Spinoff Prize 2021. Asaf Zviran’s early career was far removed …See details»
C2i Genomics is Globalizing AI-Based Cancer Diagnostics and
Oct 24, 2021 C2i Genomics Test Tube/Courtesy C2i Genomics. C2i Genomics plans to make sophisticated AI-informed cancer diagnostics and tumor monitoring available throughout the …See details»
C2i Genomics Announces Successful Evaluation of Whole Genome …
Jan 5, 2023 NEW YORK — C2i Genomics, a cancer intelligence company, today announced an extension of a collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), a global science-led …See details»
C2i Genomics Expands Data on Whole-Genome Sequencing MRD …
Apr 20, 2023 C2i's third study at AACR, with investigators from NYU Langone Health, profiled 50 stage 1 or 2 lung adenocarcinomas. Using its platform to derive a personalized assay for each …See details»
C2i Genomics raises $100M in series B to advance residual
Apr 15, 2021 To reduce the uncertainty and improve patient outcomes, C2i Genomics Inc. has raised a $100 million series B funding round led by Casdin Capital to advance software that is …See details»